资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品99.91%，提供劳务 0.09%。 10月15日，迈威生物盘中上涨2.05%，截至10:03，报45.33元/股，成交1.10亿元，换手率1.20%，总市值 181.14亿元。 资金流向方面，主力资金净流入607.26万元，特大单买入613.51万元，占比5.57%，卖出235.49万元，占 比2.14%；大单买入3098.47万元，占比28.13%，卖出2869.24万元，占比26.05%。 迈威生物今年以来股价涨124.41%，近5个交易日跌7.72%，近20日跌9.74%，近60日涨46.94%。 今年以来迈威生物已经5次登上龙虎榜，最近一次登上龙虎榜为9月2日。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌治癌、抗 癌药物、眼科概念、创新药等。 截至6月30日，迈威生物股东户 ...

截至6月30日，艾力斯股东户数1.30万，较上期增加3.61%；人均流通股34578股，较上期减少3.48%。 2025年1月-6月，艾力斯实现营业收入23.74亿元，同比增长50.57%；归母净利润10.51亿元，同比增长 60.22%。 资料显示，上海艾力斯医药科技股份有限公司位于上海市浦东新区周浦镇凌霄花路268号，成立日期 2004年3月22日，上市日期2020年12月2日，公司主营业务涉及创新药物的研发、生产和销售。主营业务 收入构成为：药品销售收入99.93%，推广服务收入0.06%，其他0.00%。 艾力斯所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌药物、抗癌治癌、创 新药、生物医药、百元股等。 10月15日，艾力斯盘中上涨2.04%，截至10:03，报104.16元/股，成交1.06亿元，换手率0.23%，总市值 468.72亿元。 资金流向方面，主力资金净流入701.42万元，特大单买入355.65万元，占比3.36%，卖出236.25万元，占 比2.23%；大单买入2547.27万元，占比24.03%，卖出1965.25万元，占比18.54%。 艾力斯今年以来股价涨 ...

10月15日，南新制药（维权）盘中上涨2.05%，截至10:02，报7.96元/股，成交2553.57万元，换手率 1.18%，总市值21.84亿元。 资金流向方面，主力资金净流出83.45万元，大单买入448.34万元，占比17.56%，卖出531.79万元，占比 20.83%。 截至6月30日，南新制药股东户数9464.00，较上期增加7.02%；人均流通股28994股，较上期减少 6.56%。2025年1月-6月，南新制药实现营业收入6184.63万元，同比减少71.28%；归母净利润-4000.23万 元，同比减少493.23%。 今年以来南新制药已经7次登上龙虎榜，最近一次登上龙虎榜为10月9日，当日龙虎榜净买入-387.09万 元；买入总计595.43万元 ，占总成交额比20.23%；卖出总计982.51万元 ，占总成交额比33.39%。 资料显示，湖南南新制药股份有限公司位于广东省广州市萝岗区开源大道196号自编1-2栋，成立日期 2006年12月27日，上市日期2020年3月26日，公司主营业务涉及专注于流行性感冒等抗病毒、传染病防 治药品,以及心脑血管疾病、糖尿病等其他重大疾病治疗药品研发、 ...

Core Viewpoint - The stock of Yaoshi Technology has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 18.33%, indicating volatility in its market performance [1]. Financial Performance - As of September 30, Yaoshi Technology reported a revenue of 920 million yuan for the first half of 2025, reflecting a year-on-year growth of 23.48%. However, the net profit attributable to shareholders decreased by 26.54% to 72.5 million yuan [2]. - Cumulatively, since its A-share listing, Yaoshi Technology has distributed a total of 231 million yuan in dividends, with 137 million yuan distributed over the past three years [3]. Shareholder Information - The number of shareholders for Yaoshi Technology as of September 30 is 46,500, a decrease of 2.94% from the previous period. The average number of circulating shares per person increased by 3.03% to 4,363 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 2.1466 million shares, a decrease of 1.2259 million shares from the previous period, while Southern CSI 1000 ETF increased its holdings by 278,200 shares to 1.4751 million shares [3]. Business Overview - Yaoshi Technology, established on December 26, 2006, and listed on November 10, 2017, is primarily engaged in the research, development, production, and sales of drug molecular building blocks. Its revenue composition includes 83.14% from drug development and commercialization services, 16.72% from drug research services, and 0.14% from other sources [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, and is involved in synthetic biology, biopharmaceuticals, innovative drugs, and cancer drugs [1].

Core Viewpoint - The stock of TEBIO experienced a decline of 2.00% on October 14, with a current price of 82.21 CNY per share and a market capitalization of 33.443 billion CNY. The company has seen a year-to-date stock price increase of 13.00% but has faced a slight decline in the recent trading periods [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion CNY, representing a year-on-year growth of 26.96%. The net profit attributable to shareholders was 428 million CNY, showing a year-on-year increase of 40.60% [2]. - Since its A-share listing, TEBIO has distributed a total of 577 million CNY in dividends, with 506 million CNY distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period. The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. - The major shareholders include ETFs such as 华夏上证科创板50成份ETF and 易方达上证科创板50ETF, which have increased their holdings [3]. Company Overview - TEBIO, established on August 7, 1996, and listed on January 17, 2020, is based in Xiamen, Fujian Province. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with a revenue composition of 86.85% from antiviral drugs and 12.87% from blood/cancer drugs [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category [1].

Core Points - Junshi Bioscience's stock price has increased by 42.01% year-to-date but has seen a decline of 5.34% in the last five trading days and 19.15% over the past 20 days [2] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, an increase of 36.01% year-on-year [2] Company Overview - Junshi Bioscience, established on December 27, 2012, and listed on July 15, 2020, is located in Shanghai and focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The company's main revenue sources include drug sales (90.67%), technology licensing and royalties (8.74%), and technical services and others (0.59%) [2] Market Activity - As of October 13, Junshi Bioscience's stock was trading at 38.81 yuan per share, with a market capitalization of 39.846 billion yuan [1] - The stock experienced a net outflow of 12.9063 million yuan in principal funds, with large orders showing a buy of 30.8144 million yuan and a sell of 43.5137 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders for Junshi Bioscience was 31,200, an increase of 5.88% from the previous period, with an average of 24,543 circulating shares per person, a decrease of 5.56% [2] - The top ten circulating shareholders include various ETFs, with notable changes in holdings, such as a decrease of 536,700 shares for 华夏上证科创板50成份ETF and an increase of 630,000 shares for 易方达上证科创板50ETF [3]

Core Insights - The stock price of Maiwei Bio has increased by 129.75% year-to-date but has recently experienced a decline of 9.36% over the past five trading days and 14.40% over the past 20 days [2] - The company reported a revenue of 1.01 billion yuan for the first half of 2025, a year-on-year decrease of 12.43%, and a net profit attributable to shareholders of -5.51 billion yuan, down 23.90% year-on-year [2] Company Overview - Maiwei Bio, established on May 12, 2017, and listed on January 18, 2022, is located in the Shanghai Free Trade Zone and specializes in the research, production, and sales of therapeutic biological products [2] - The company's main revenue source is from product sales, accounting for 99.91%, with service provision making up 0.09% [2] - Maiwei Bio operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in concepts such as AI medicine, ophthalmology, and innovative drugs [2] Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders for Maiwei Bio increased by 11.66% to 17,900, with an average of 11,379 circulating shares per shareholder, a decrease of 10.44% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 4.74 million shares, and new entrants such as Xingquan Helun Mixed A and Penghua Medical Technology Stock A [3] - Several funds, including HSBC Jintrust, have exited the top ten circulating shareholders list [3]

Core Viewpoint - The stock of Jibeier has experienced fluctuations, with a year-to-date increase of 59.41% but a recent decline in the last five and twenty trading days [1] Group 1: Stock Performance - As of October 10, Jibeier's stock price was 34.88 CNY per share, with a market capitalization of 6.956 billion CNY [1] - The stock has seen a recent decline of 2.02% in intraday trading, with a trading volume of 37.4161 million CNY and a turnover rate of 0.53% [1] - Year-to-date, the stock has increased by 59.41%, but it has decreased by 2.43% over the last five trading days and 10.01% over the last twenty trading days [1] Group 2: Financial Performance - For the first half of 2025, Jibeier reported a revenue of 455 million CNY, representing a year-on-year growth of 4.90% [2] - The net profit attributable to shareholders for the same period was 149 million CNY, showing a year-on-year increase of 22.38% [2] Group 3: Shareholder Information - As of June 30, the number of Jibeier shareholders was 6,003, a decrease of 17.68% from the previous period [2] - The average number of circulating shares per shareholder increased by 21.47% to 33,221 shares [2] Group 4: Dividend Information - Jibeier has distributed a total of 476 million CNY in dividends since its A-share listing, with 296 million CNY distributed over the past three years [3]

Core Viewpoint - Yiling Pharmaceutical's stock has shown a slight increase of 2.01% on October 9, 2023, with a current price of 16.21 CNY per share and a total market capitalization of 27.08 billion CNY [1] Financial Performance - For the first half of 2025, Yiling Pharmaceutical reported a revenue of 4.04 billion CNY, a year-on-year decrease of 12.26%, while the net profit attributable to shareholders increased by 26.03% to 669 million CNY [2] - The company has cumulatively distributed 3.95 billion CNY in dividends since its A-share listing, with 1.34 billion CNY distributed in the last three years [3] Stock Market Activity - As of October 9, 2023, Yiling Pharmaceutical's stock has increased by 1.25% year-to-date, with a 0.87% increase over the last five trading days, a 2.11% decrease over the last 20 days, and a 9.53% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 64.05 million CNY on January 6 [1] Shareholder Information - As of June 30, 2025, Yiling Pharmaceutical had 170,100 shareholders, a decrease of 8.18% from the previous period, with an average of 8,093 circulating shares per shareholder, an increase of 8.91% [2] - The fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 17.59 million shares, a decrease of 5.68 million shares from the previous period [3]

Core Viewpoint - Yifang Bio's stock price has experienced significant fluctuations, with a year-to-date increase of 129.17%, but a recent decline of 9.61% over the past five trading days [1] Group 1: Stock Performance - As of October 9, Yifang Bio's stock price was 30.48 CNY per share, with a market capitalization of 17.628 billion CNY [1] - The stock has seen a trading volume of 185 million CNY and a turnover rate of 1.42% [1] - Year-to-date, the stock has risen by 129.17%, but has declined by 9.61% in the last five trading days, 29.22% in the last 20 days, and 4.00% in the last 60 days [1] Group 2: Financial Metrics - For the first half of 2025, Yifang Bio reported revenue of 19.1638 million CNY, a year-on-year increase of 28.85%, while the net profit attributable to shareholders was -119 million CNY, reflecting a 44.25% year-on-year increase in losses [2] - The company has appeared on the stock market's "Dragon and Tiger List" three times this year, with the most recent appearance on July 11, where it recorded a net purchase of 68.8706 million CNY [1] Group 3: Shareholder Information - As of June 30, 2025, Yifang Bio had 9,790 shareholders, a decrease of 7.28% from the previous period, with an average of 40,990 circulating shares per shareholder, an increase of 7.85% [2] - Notable institutional shareholders include Huatai-PineBridge Innovation Medicine Mixed A, which is the fourth largest shareholder with 9.9619 million shares, and Central Clearing Hong Kong Limited, which is a new shareholder with 8.0541 million shares [2]